Micropaque Suspension (Barium Sulfate)

Barium sulfate consists of insoluble particles with a high atomic number. When the suspension is introduced into the GI lumen, the particles adhere to the mucosal surface, creating a dense, X‑ray‑absorbing layer. This radiopaque coating highlights the shape and contour of the gastrointestinal tract on radiographic images.

The appropriate amount of Micropaque Suspension is set by the prescribing clinician based on the specific imaging study, patient age, weight, and clinical condition. Dosage regimens are individualized and should follow the radiology department’s protocol or the physician’s written order.

Safety data for Micropaque Suspension in pregnancy and lactation are limited. It should only be used when clearly needed and after a careful risk‑benefit assessment by the treating physician. Breastfeeding mothers should consult their healthcare provider before administration.

To place an order, submit an enquiry on the Micropaque product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Micropaque (barium sulfate) is a non‑ionic, insoluble contrast medium used primarily for gastrointestinal studies, whereas iodinated agents are water‑soluble and suited for vascular, cardiac and soft‑tissue imaging. Barium provides superior mucosal coating for GI tract visualization but is not used for intravascular applications.

Store Micropaque Suspension at room temperature, preferably below 25 °C. Keep the container tightly sealed, protect it from moisture and direct sunlight, and retain it in the original packaging until use to maintain suspension stability.

The suspension is given orally as a drink or introduced rectally via a catheter, depending on the imaging study. Administration is performed under the supervision of radiology staff, who ensure the patient ingests or receives the appropriate volume for optimal coating of the target gastrointestinal segment.

Serious risks include barium impaction, which can obstruct the gastrointestinal tract and may require medical intervention, allergic reactions such as rash or swelling, and aspiration of barium into the lungs, potentially leading to respiratory complications. Prompt medical evaluation is essential if any of these occur.

Patients with known hypersensitivity to barium sulfate, those with suspected or confirmed bowel obstruction, perforation, or severe inflammatory bowel disease should avoid Micropaque. Additionally, individuals who cannot safely swallow or retain the suspension, such as those with compromised airway protection, are contraindicated.